Navigation Links
AcelRx Pharmaceuticals Reports Fourth Quarter and Full-Year 2010 Financial Results

REDWOOD CITY, Calif., March 24, 2011 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), ("AcelRx"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute or breakthrough pain, today reported financial results for the fourth quarter and year ended December 31, 2010.

Net loss for the fourth quarter of 2010 was $3.5 million, or $5.23 per common share, compared with a net loss of $3.7 million, or $6.05 per common share, for the fourth quarter of 2009. Net loss for the year ended December 31, 2010 was $14.3 million, or $21.84 per common share, compared to a net loss of $20.1 million, or $34.93 per common share, for the year ended December 31, 2009.

Research and development expenses for the twelve and three months ended December 31, 2010 totaled $8.2 million and $1.9 million, compared to $15.5 million and $2.3 million for the twelve and three months ended December 31, 2009. General and administrative expenses were $4.0 million and $1.0 million for the year and quarter ended December 31, 2010, compared to $3.5 million and $1.0 million for the year and quarter ended December 31, 2009.

As of December 31, 2010, AcelRx had cash, cash equivalents and short-term investments of $3.7 million, compared to $12.5 million as of December 31, 2009. On February 16, 2011, AcelRx closed its initial public offering of 8.0 million shares of common stock resulting in net proceeds to AcelRx of $35.6 million.  We intend to utilize these funds primarily for advancement of our lead program, our hospital-based, patient-controlled analgesia (PCA) product, the Sufentanil NanoTab PCA System (ARX-01).

"We are pleased with our progress towards initiating the Phase 3 program for ARX-01 in acute post-operative pain," said Richard King, President and Chief Executive Officer of AcelRx. "We anticipate initiating enrollment in the first Phase 3 study of ARX-01, an abdominal surgery efficacy study, in the second half of 2011.  Further, we anticipate starting our second Phase 3 study, a head-to-head trial comparing ARX-01 to the current standard of care, intravenous (IV) PCA morphine, in early 2012. Top-line data from both trials is expected in the first half of 2012."

"ARX-01 is a preprogrammed, handheld, sublingual PCA system delivering the high therapeutic index opioid, sufentanil, that has been designed to address the need for effective and well tolerated post-operative pain control in the hospital setting, and to overcome the deficiencies of the current standard of care, IV PCA. The 2010 Decision Resources Acute Pain Report projects that the post-operative pain market for the United States, Europe and Japan will reach $6.5 billion in 2018. We believe that ARX-01 has the opportunity to become the new standard of care for patient-controlled management of moderate-to-severe post-operative pain," said Mr. King.

Financial OutlookAcelRx anticipates that research and development expenses will increase over the next several years as AcelRx seeks to complete the Phase 3 development of ARX-01 and subsequently advance the development of its other product candidates for cancer breakthrough pain and mild sedation for painful procedures in a physician's office, ARX-02 and ARX-03. AcelRx does not intend to initiate the third ARX-01 Phase 3 study, an efficacy study in orthopedic hip and knee replacement surgeries, nor advance the development of ARX-02 and ARX-03 until additional funding is obtained. Additionally, AcelRx anticipates increases in general and administrative expenses due to costs associated with operating as a public company.

AcelRx believes its current cash, cash equivalents and short-term investments, including initial public offering net proceeds of $35.6 million, are sufficient to fund operations through at least the second quarter of 2012.

About AcelRx Pharmaceuticals, Inc. Based in Redwood City, CA, AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain. AcelRx's lead product candidate, the ARX-01 Sufentanil NanoTab(TM) PCA System, which has completed Phase 2 clinical development, is designed to solve the problems associated with post-operative intravenous patient-controlled analgesia (IV PCA) which has been shown to cause harm to patients following surgery because of the side effects of morphine, the invasive IV route of delivery and the inherent potential for programming and delivery errors associated with the complexity of infusion pumps. AcelRx has two additional product candidates which have completed Phase 2 clinical development: ARX-02 for the treatment of cancer breakthrough pain, and ARX-03 for providing mild sedation, anxiety reduction and pain relief for patients undergoing painful procedures in a physician's office.

Forward Looking Statements This press release contains forward-looking statements, including, but not limited to, statements related to AcelRx Pharmaceuticals' financial performance, clinical trial update and future financial performance, including 2011 financial outlook, and statements relating to the timing of the clinical trials and product candidate development.  These forward-looking statements are based on the company's current expectations and inherently involve significant risks and uncertainties.  AcelRx Pharmaceuticals' actual results and the timing of events could differ materially from those anticipated in such forward looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to: the success, cost and timing of AcelRx Pharmaceutical's product development activities and clinical trials; its ability to obtain and maintain regulatory approval of its product candidates; its ability to obtain funding for its operations; its plans to research, develop and commercialize its product candidates; its ability to attract collaborators with development, regulatory and commercialization expertise; the accuracy of AcelRx Pharmaceutical's estimates regarding expenses, capital requirements and needs for financing; and other risks detailed in the "Risk Factors" and elsewhere in AcelRx Pharmaceuticals' Securities and Exchange Commission filings and reports, including its Registration Statement on Form S-1 (including a prospectus) and its Annual Report on Form 10-K for the year ended December 31, 2010, when it becomes available.  AcelRx Pharmaceuticals undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in its expectations. Balance Sheets(in thousands, except share and per share data) December 31,20102009ASSETSCURRENT ASSETS:Cash and cash equivalents

7,150Short-Term Invesments

6275,396Prepaid expenses and other current assets

2,097397Total Current Assets$
5,779$  12,943Property and equipment, net

8001,280Restricted cash

205205Other assets


917Accrued liabilities

859369Convertible notes (1)

6,805-Long-term debt, current portion

5,2044,726Total current liabilities$  13,411$
,012Deferred rent

245425Long-term debt, net of current portion

-5,008Call option liability

596-Convertible preferred stock warrant liability

2,529169TOTAL LIABILITIES$  16,781$  11,614STOCKHOLDERS' EQUITY (DEFICIT):Convertible preferred stock, $0.001 par value - 46,736,123 shares authorized as of  December 31, 2010 and 2009; 7,151,802 and 7,132,527 shares issued and outstanding as of December 31, 2010 and 2009

$  55,941$  55,871Common stock, $0.001 par value - 71,000,000 shares authorized as of December 31, 2010 and 2009; 674,353 and 620,116 shares issued and outstanding as of December 31, 2010 and 2009

33Additional paid-in capital

2,6681,224Acumulated other comprehensive income (loss)

-(2)Deficit accumulated during the development stage

(68,563)(54,219)TOTAL STOCKHOLDERS' EQUITY (DEFICIT)$ (9,951)$
,830$  14,491(1)The convertible debt balance is comprised of $8 million in convertible notes outstanding as of December 31, 2010 less $1.2 million in debt discount.  The principal and the interest under these convertible notes were subsequently converted into common stock upon our initial public offering in February 2011.Statements of Operations(in thousands, except share and per share data)Three Months Ended December 31,Year Ended December 31,2010200920102009Operating Expenses:Research and development

$1,884$2,322$8,193$15,502General and administrative

9601,0193,9933,529Total operating expenses $2,844$3,341$12,186$19,031Loss from operations ($2,844)($3,341)($12,186)($19,031)Interest income

20433Interest expense

(741)(277)(1,397)(1,242)Other income (expense), net

59(79)(765)121Net loss ($3,524)($3,697)($14,344)($20,119)Net loss per share of common stock, basic and diluted ($5.23)($6.05)($21.84)($34.93)Shares used in computing net loss per share of common stock, basic and diluted (1)

674,353610,987656,650576,021(1) Weighted-average number of common shares used in calculating net loss per common share – basic and diluted for the year ended December 31, 2010 excludes (i) the 8,000,000 shares of common stock issued in the initial public offering in February 2011, (ii) 8,555,713 shares of common stock resulting from the conversion of our convertible preferred stock to common shares upon the closing of the initial public offering, and (iii) the issuance of 2,141,684 shares of common stock resulting from the conversion of $8 million in convertible notes, and net exercise of the associated warrants. Following the initial public offering, the Company had 19,371,750 shares of common stock outstanding.

SOURCE AcelRx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. AcelRx Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference
2. AcelRx Pharmaceuticals Announces Pricing of Its Initial Public Offering
3. AcelRx Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering
4. AcelRx Announces Positive Phase 2 Results From a Study of ARX-02 Sufentanil NanoTab(TM) Breakthrough Pain Management System in Treating Cancer Breakthrough Pain
5. AcelRx to Present at the Lazard 6th Annual Healthcare Conference
6. AcelRx Programs to be Featured in Oral Presentations at the American Society of Anesthesiologists 2009 Annual Meeting
7. AcelRx Announces Positive Phase 2 Results from a Study of ARX-01 Sufentanil NanoTabs in Treating Post-Operative Pain
8. AcelRx Initiates a Phase 2 Study to Evaluate Functionality of Its ARX-01 Sufentanil NanoTab PCA System
9. AcelRx Pharmaceuticals Reports Positive Results from a Clinical Trial of Sublingual Sufentanil/Triazolam NanoTab(TM) Combination (ARX-03) in Treating Procedural Pain and Anxiety
10. Valeant Pharmaceuticals Extends Contract with J. Michael Pearson as CEO and Appoints Him as Chairman of the Board
11. Auxilium Pharmaceuticals, Inc. and Asahi Kasei Pharma Corporation Enter Agreement to Develop, Commercialize and Supply XIAFLEX® In Japan
Post Your Comments:
(Date:11/26/2015)... 26, 2015 Research and Markets ( ... Wound Care Market by Type (Dressings, Therapy Devices, Active ... Facility, Out-Patient Facility), and Geography - Global Forecast to ... --> --> The purpose of ... forecast of the global advanced wound care market. It ...
(Date:11/26/2015)... 26, 2015 ... adds "Global Repaglinide Industry 2015 ... on China Repaglinide Market, 2010-2019" reports ... and information to its online business ... . --> ...
(Date:11/26/2015)... 2015 Research and Markets ( ... "2016 Future Horizons and Growth Strategies in the ... Country Segment Forecasts, Competitive Intelligence, Emerging Opportunities" ... --> --> This new 247-page ... therapeutic drug monitoring market, including emerging tests, technologies, ...
Breaking Medicine Technology:
(Date:11/28/2015)... ... ... Beginning November 30th at 6:00 a.m. EST until 11:59 p.m. EST, customers ... up to 20% off orders $80 or more to free gifts with purchases, there will ... As a competitive e-commerce website for skin care and cosmetic needs, customers will save on ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... According to ... are not changing the way that they are handling security in light of the ... and security presence in an attempt to stop an attack from reaching U.S. soil. ...
(Date:11/27/2015)... , ... November 27, 2015 , ... Lizzie’s Lice Pickers ... company is offering customers 10% off of their purchase of lice treatment product. In ... full price. According to a company spokesperson. “Finding lice is a sure way to ...
(Date:11/27/2015)... Wilmington, DE (PRWEB) , ... November 27, 2015 ... ... a member of the well-respected Microsoft Dynamics SL User Group (MSDSLUG). Recognized as ... is an independent group of Microsoft Dynamics SL software users, partners, industry experts ...
(Date:11/27/2015)... ... November 27, 2015 , ... The men and ... nonprofit healthcare organizations in the country. They have overseen financial turnarounds, shown commitment ... advance the healthcare industry as a whole through their advocacy and professional efforts. ...
Breaking Medicine News(10 mins):